Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2025 of 2051 entries
View as:

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

Phase: N/A Priority: Normal
NCT ID: NCT00511667 Org: User:
Start: 05/31/07 End: 04/30/08 Due: 04/30/09

Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00423150 Org: User:
Start: 01/26/07 End: 06/11/09 Due: 06/11/10

A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)

Phase: N/A Priority: Normal
NCT ID: NCT00092313 Org: User:
Start: 06/30/02 End: 09/30/02 Due: 09/30/03

A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)

Phase: N/A Priority: Normal
NCT ID: NCT06586606 Org: User:
Start: 10/03/24 End: 12/10/24 Due: 12/10/25

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00086515 Org: User:
Start: 06/30/04 End: 02/02/07 Due: 02/02/08

A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00863590 Org: User:
Start: 06/30/04 End: 08/31/08 Due: 08/31/09

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

Phase: N/A Priority: Normal
NCT ID: NCT06619678 Org: User:
Start: 01/17/24 End: 06/23/24 Due: 06/23/25

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Phase: N/A Priority: Normal
NCT ID: NCT00848718 Org: User:
Start: 03/17/09 End: 05/17/12 Due: 05/17/13

An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)

Phase: N/A Priority: Normal
NCT ID: NCT03055338 Org: User:
Start: 03/08/17 End: 01/09/18 Due: 01/09/19

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

Phase: N/A Priority: Normal
NCT ID: NCT01863667 Org: User:
Start: 07/08/13 End: 04/03/14 Due: 04/03/15

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Phase: N/A Priority: Normal
NCT ID: NCT05382325 Org: User:
Start: 06/16/22 End: 07/31/26 Due: 07/31/27

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Phase: N/A Priority: Normal
NCT ID: NCT01755156 Org: User:
Start: 01/11/13 End: 03/16/16 Due: 03/16/17

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

Phase: N/A Priority: Normal
NCT ID: NCT06703463 Org: User:
Start: 10/17/23 End: 02/02/24 Due: 02/02/25

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

Phase: N/A Priority: Normal
NCT ID: NCT03351608 Org: User:
Start: 02/12/18 End: 01/28/20 Due: 01/28/21

A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

Phase: N/A Priority: Normal
NCT ID: NCT00551915 Org: User:
Start: 05/31/01 End: 01/31/03 Due: 01/31/04

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092872 Org: User:
Start: 11/30/03 End: 02/28/05 Due: 02/28/06

MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

Phase: N/A Priority: Normal
NCT ID: NCT01852825 Org: User:
Start: 11/27/13 End: 08/03/15 Due: 08/03/16

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

Phase: N/A Priority: Normal
NCT ID: NCT02611960 Org: User:
Start: 04/18/16 End: 09/30/22 Due: 09/30/23

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Phase: N/A Priority: Normal
NCT ID: NCT05630755 Org: User:
Start: 02/17/23 End: 08/04/28 Due: 08/04/29

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Phase: N/A Priority: Normal
NCT ID: NCT00543543 Org: User:
Start: 09/24/07 End: 07/07/16 Due: 07/07/17

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Phase: N/A Priority: Normal
NCT ID: NCT04308304 Org: User:
Start: 02/16/21 End: 05/18/22 Due: 05/18/23

Stocrin Re-examination Study (0831-028)

Phase: N/A Priority: Normal
NCT ID: NCT01065792 Org: User:
Start: 03/31/09 End: 02/28/14 Due: 02/28/15

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03950674 Org: User:
Start: 02/22/16 End: 06/22/23 Due: 06/22/24

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Phase: N/A Priority: Normal
NCT ID: NCT03833427 Org: User:
Start: 03/18/19 End: 06/28/22 Due: 06/28/23

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

Phase: N/A Priority: Normal
NCT ID: NCT03885934 Org: User:
Start: 06/25/19 End: 12/09/20 Due: 12/09/21